The Big Four are hiking credit card costs and cutting rewards as RBA reforms squeeze fee income, but fresh perks offer some ...

Despite its due late-stage stem cell trial failures, Cynata is passing the hat for just over $900,000 in an underwritten ...

Rare earths and critical minerals are expected to take a growing slice of Australia's resources pie in the years to come.

Australia has a rich history of mineral sands mining, with a new generation of ASX players now chasing the next supply wave.

Island’s shot at gaining US FDA approval for antiviral Galidesivir for Marburg virus under the Animal Rule presents lucrative opportunities ...

The ASX snapped a three-day winning streak as banks and miners weighed, while uranium stocks lit up after Google’s big ...

Renascor (ASX:RNU) has produced battery-grade purified spherical graphite (PSG) at its Adelaide demonstration plant.

Core Lithium's junior neighbour, which trades at a fraction of its market cap, could rerate according to an Aussie mining ...

Amid a rash of disappointing late-stage clinical study results, drug developers are smashing out some decent mid-stage success.

Thrive Tribe is having a crack at making veteran healthcare easier to navigate as government spending on care ramps up.

UniSuper’s chief investment officer has no plans to invest in Firmus Technologies’ $44bn float, warning that loss-making AI companies will keep tapping investors for cash for years.

Amid stubbornly high syphilis rates, pandemic-era Atomo is developing a point-of-care assay to detect active cases of the ...